Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to U. Capitanio et al.
Oza B, Eisen T, Stewart GD, Bex A, Royston P, Meade A; authors on the SORCE TMG. Oza B, et al. Among authors: bex a. J Clin Oncol. 2023 Jan 20;41(3):704-706. doi: 10.1200/JCO.22.01124. Epub 2022 Sep 27. J Clin Oncol. 2023. PMID: 36166721 No abstract available.
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer.
Sharpe K, Stewart GD, Mackay A, Van Neste C, Rofe C, Berney D, Kayani I, Bex A, Wan E, O'Mahony FC, O'Donnell M, Chowdhury S, Doshi R, Ho-Yen C, Gerlinger M, Baker D, Smith N, Davies B, Sahdev A, Boleti E, De Meyer T, Van Criekinge W, Beltran L, Lu YJ, Harrison DJ, Reynolds AR, Powles T. Sharpe K, et al. Among authors: bex a. Clin Cancer Res. 2013 Dec 15;19(24):6924-34. doi: 10.1158/1078-0432.CCR-13-1631. Epub 2013 Oct 15. Clin Cancer Res. 2013. PMID: 24130073 Clinical Trial.
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock AL, Nanda J, O'Donnell M, Mackay A, Mullen P, McNeill SA, Riddick AC, Aitchison M, Berney D, Bex A, Overton IM, Harrison DJ, Powles T. Stewart GD, et al. Among authors: bex a. Eur Urol. 2014 Nov;66(5):956-63. doi: 10.1016/j.eururo.2014.04.007. Epub 2014 May 10. Eur Urol. 2014. PMID: 24821582 Free PMC article. Clinical Trial.
Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.
Stewart GD, O'Mahony FC, Laird A, Eory L, Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA, Riddick AC, Berney D, Bex A, Aitchison M, Overton IM, Harrison DJ, Powles T. Stewart GD, et al. Among authors: bex a. Clin Cancer Res. 2015 Sep 15;21(18):4212-23. doi: 10.1158/1078-0432.CCR-15-0207. Epub 2015 May 26. Clin Cancer Res. 2015. PMID: 26015515
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Kramar A, et al. Among authors: bex a. Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Ann Oncol. 2015. PMID: 26371288 Free article. Review.
Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.
Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandéz-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A. Dabestani S, et al. Among authors: bex a. Eur Urol Focus. 2019 Sep;5(5):857-866. doi: 10.1016/j.euf.2018.02.010. Epub 2018 Mar 7. Eur Urol Focus. 2019. PMID: 29525381
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A. Sun M, et al. Among authors: bex a. Eur Urol. 2018 Nov;74(5):611-620. doi: 10.1016/j.eururo.2018.05.002. Epub 2018 May 18. Eur Urol. 2018. PMID: 29784193 Free PMC article.
External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A. Marconi L, et al. Among authors: bex a. World J Urol. 2018 Dec;36(12):1973-1980. doi: 10.1007/s00345-018-2427-z. Epub 2018 Aug 1. World J Urol. 2018. PMID: 30069581
368 results